Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Gastrointestinal cancers


Educational programs building upon the most current research and professional practice recommendations in gastrointestinal cancers, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.



Recent symposia

ILCA 2019: Independent satellite symposium

Improving the management of hepatocellular carcinoma: best practice and future directions

Chaired by Andrew Zhu with Peter Galle and Richard Finn

Faculty interviews, including take-home messages from the symposium, are now available.

Case studies

23-03-2019 | Pancreatic cancer | Case study | Collection

New options in metastatic pancreatic cancer: Interactive patient cases

These two case studies are intended for global medical, surgical and radiation oncologists, gastroenterologists, and other healthcare providers involved in the management of patients with pancreatic cancer, and any other clinicians involved in the diagnosis, treatment and follow-up of patients with PDAC.

Developed with an independent educational grant from Shire and supported by Servier.

Related programs

18-12-2017 | Gastric cancer | Scientific summary | Collection

Gastric cancer care: From evidence to practice

This symposium, chaired by Ian Chau, discussed the latest in gastric cancer treatment and molecular analysis, and provided advice on how to incorporate the ever-changing current optimal therapeutic strategies into everyday clinical practice, using case presentations to stimulate interactive discussion.

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company.

21-04-2017 | Gastric cancer | Scientific summary | Collection

Optimal treatment in metastatic gastric cancer

This session, held at the 17th Pan Arab Cancer Conference (PACC) in Algiers, Algeria, and chaired by Eric Van Cutsem, discussed treatment options for patients with metastatic gastric cancer, ranging from cytotoxic agents to targeted therapy, antiangiogenic agents and immune checkpoint inhibitors.

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company.

16-12-2016 | Gastric cancer | Scientific summary | Collection

Advances in gastric cancer

This symposium, chaired by Ian Chau, discussed the latest surgical and oncologic treatments for gastric cancer in the context of an increasingly complex treatment landscape, including patient and tumour characteristics, clinical guidelines, and novel clinical data, with special focus on the multidisciplinary care team setting.

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company.

Image Credits